pser19 mlc2 Search Results


pser19 mlc2  (Cell Signaling Technology Inc)
96
Cell Signaling Technology Inc pser19 mlc2
(a) Percentage of alive primary melanoma WM983A cells and metastatic melanoma WM983B cells after a first round of migration in transwells through 8-μm pores (b) Percentage of alive WM983A and WM983B cells after a second round of migration in transwells through 5-μm pores upon staurosporin treatment. n = 180 and 213 cells, respectively (N = 1). (c) Representative pictures of WM983A and WM983B cells expressing GFP-NLS (green) and stained for caspase-3 (magenta) and DNA (blue) after a second round of migration in transwells through 5-μm pores in the presence or absence of staurosporin. Scale bars, 30 μm. (d) Resolved cell lysates of WM983A and WM983B cells after treatment with ROCK inhibitor (ROCKi) GSK269962A were examined by western blotting with antisera raised against GAPDH, <t>MLC2</t> and pMLC2. (e) Representative pictures of WM983A and WM983B cells treated with ROCKi and stained for pMLC2 (magenta), lamin A/C (green) and DNA (blue) after a first round of transwell migration through 8-μm pores. Scale bars, 30 μm. (f,g) Percentage of WM983B cells that translocated their nuclei (f) and displayed nuclear envelope blebs (g) after a second round of transwell migration through 8-μm pores upon ROCK inhibitor (ROCKi) GSK269962A treatment. n = 787 and 691 cells, respectively. Bar charts show means and error bars represent S.E.M. from N = 3 independent experiements, unless otherwise stated. P-values calculated by unpaired two-tailed t-test (a,f,g). *p < 0.05, **p < 0.01. Unprocessed western blots, numerical data and exact p-values are available in the Source Data.
Pser19 Mlc2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pser19+mlc2/Phospho-Myosin+Light+Chain+2+(Ser19)+Antibody/pmc09859759-264-31-35
Average 96 stars, based on 1 article reviews
pser19 mlc2 - by Bioz Stars, 2026-09
96/100 stars
  Buy from Supplier
rabbit anti human diphosphorylated myosin light chain 2  (Cell Signaling Technology Inc)
96
Cell Signaling Technology Inc rabbit anti human diphosphorylated myosin light chain 2
(a) Percentage of alive primary melanoma WM983A cells and metastatic melanoma WM983B cells after a first round of migration in transwells through 8-μm pores (b) Percentage of alive WM983A and WM983B cells after a second round of migration in transwells through 5-μm pores upon staurosporin treatment. n = 180 and 213 cells, respectively (N = 1). (c) Representative pictures of WM983A and WM983B cells expressing GFP-NLS (green) and stained for caspase-3 (magenta) and DNA (blue) after a second round of migration in transwells through 5-μm pores in the presence or absence of staurosporin. Scale bars, 30 μm. (d) Resolved cell lysates of WM983A and WM983B cells after treatment with ROCK inhibitor (ROCKi) GSK269962A were examined by western blotting with antisera raised against GAPDH, <t>MLC2</t> and pMLC2. (e) Representative pictures of WM983A and WM983B cells treated with ROCKi and stained for pMLC2 (magenta), lamin A/C (green) and DNA (blue) after a first round of transwell migration through 8-μm pores. Scale bars, 30 μm. (f,g) Percentage of WM983B cells that translocated their nuclei (f) and displayed nuclear envelope blebs (g) after a second round of transwell migration through 8-μm pores upon ROCK inhibitor (ROCKi) GSK269962A treatment. n = 787 and 691 cells, respectively. Bar charts show means and error bars represent S.E.M. from N = 3 independent experiements, unless otherwise stated. P-values calculated by unpaired two-tailed t-test (a,f,g). *p < 0.05, **p < 0.01. Unprocessed western blots, numerical data and exact p-values are available in the Source Data.
Rabbit Anti Human Diphosphorylated Myosin Light Chain 2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pser19+mlc2/Phospho-Myosin+Light+Chain+2+(Thr18%2FSer19)+Antibody/pm25131196-113-5-15
Average 96 stars, based on 1 article reviews
rabbit anti human diphosphorylated myosin light chain 2 - by Bioz Stars, 2026-09
96/100 stars
  Buy from Supplier
pser19 myosin light chain 2  (Cell Signaling Technology Inc)
96
Cell Signaling Technology Inc pser19 myosin light chain 2
(a) Percentage of alive primary melanoma WM983A cells and metastatic melanoma WM983B cells after a first round of migration in transwells through 8-μm pores (b) Percentage of alive WM983A and WM983B cells after a second round of migration in transwells through 5-μm pores upon staurosporin treatment. n = 180 and 213 cells, respectively (N = 1). (c) Representative pictures of WM983A and WM983B cells expressing GFP-NLS (green) and stained for caspase-3 (magenta) and DNA (blue) after a second round of migration in transwells through 5-μm pores in the presence or absence of staurosporin. Scale bars, 30 μm. (d) Resolved cell lysates of WM983A and WM983B cells after treatment with ROCK inhibitor (ROCKi) GSK269962A were examined by western blotting with antisera raised against GAPDH, <t>MLC2</t> and pMLC2. (e) Representative pictures of WM983A and WM983B cells treated with ROCKi and stained for pMLC2 (magenta), lamin A/C (green) and DNA (blue) after a first round of transwell migration through 8-μm pores. Scale bars, 30 μm. (f,g) Percentage of WM983B cells that translocated their nuclei (f) and displayed nuclear envelope blebs (g) after a second round of transwell migration through 8-μm pores upon ROCK inhibitor (ROCKi) GSK269962A treatment. n = 787 and 691 cells, respectively. Bar charts show means and error bars represent S.E.M. from N = 3 independent experiements, unless otherwise stated. P-values calculated by unpaired two-tailed t-test (a,f,g). *p < 0.05, **p < 0.01. Unprocessed western blots, numerical data and exact p-values are available in the Source Data.
Pser19 Myosin Light Chain 2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pser19+mlc2/Myosin+Light+Chain+2+Antibody/10__1091_slash_mbc__e13___03___0148-156-0-6
Average 96 stars, based on 1 article reviews
pser19 myosin light chain 2 - by Bioz Stars, 2026-09
96/100 stars
  Buy from Supplier

Image Search Results


(a) Percentage of alive primary melanoma WM983A cells and metastatic melanoma WM983B cells after a first round of migration in transwells through 8-μm pores (b) Percentage of alive WM983A and WM983B cells after a second round of migration in transwells through 5-μm pores upon staurosporin treatment. n = 180 and 213 cells, respectively (N = 1). (c) Representative pictures of WM983A and WM983B cells expressing GFP-NLS (green) and stained for caspase-3 (magenta) and DNA (blue) after a second round of migration in transwells through 5-μm pores in the presence or absence of staurosporin. Scale bars, 30 μm. (d) Resolved cell lysates of WM983A and WM983B cells after treatment with ROCK inhibitor (ROCKi) GSK269962A were examined by western blotting with antisera raised against GAPDH, MLC2 and pMLC2. (e) Representative pictures of WM983A and WM983B cells treated with ROCKi and stained for pMLC2 (magenta), lamin A/C (green) and DNA (blue) after a first round of transwell migration through 8-μm pores. Scale bars, 30 μm. (f,g) Percentage of WM983B cells that translocated their nuclei (f) and displayed nuclear envelope blebs (g) after a second round of transwell migration through 8-μm pores upon ROCK inhibitor (ROCKi) GSK269962A treatment. n = 787 and 691 cells, respectively. Bar charts show means and error bars represent S.E.M. from N = 3 independent experiements, unless otherwise stated. P-values calculated by unpaired two-tailed t-test (a,f,g). *p < 0.05, **p < 0.01. Unprocessed western blots, numerical data and exact p-values are available in the Source Data.

Journal: Nature Cell Biology

Article Title: LAP1 supports nuclear adaptability during constrained melanoma cell migration and invasion

doi: 10.1038/s41556-022-01042-3

Figure Lengend Snippet: (a) Percentage of alive primary melanoma WM983A cells and metastatic melanoma WM983B cells after a first round of migration in transwells through 8-μm pores (b) Percentage of alive WM983A and WM983B cells after a second round of migration in transwells through 5-μm pores upon staurosporin treatment. n = 180 and 213 cells, respectively (N = 1). (c) Representative pictures of WM983A and WM983B cells expressing GFP-NLS (green) and stained for caspase-3 (magenta) and DNA (blue) after a second round of migration in transwells through 5-μm pores in the presence or absence of staurosporin. Scale bars, 30 μm. (d) Resolved cell lysates of WM983A and WM983B cells after treatment with ROCK inhibitor (ROCKi) GSK269962A were examined by western blotting with antisera raised against GAPDH, MLC2 and pMLC2. (e) Representative pictures of WM983A and WM983B cells treated with ROCKi and stained for pMLC2 (magenta), lamin A/C (green) and DNA (blue) after a first round of transwell migration through 8-μm pores. Scale bars, 30 μm. (f,g) Percentage of WM983B cells that translocated their nuclei (f) and displayed nuclear envelope blebs (g) after a second round of transwell migration through 8-μm pores upon ROCK inhibitor (ROCKi) GSK269962A treatment. n = 787 and 691 cells, respectively. Bar charts show means and error bars represent S.E.M. from N = 3 independent experiements, unless otherwise stated. P-values calculated by unpaired two-tailed t-test (a,f,g). *p < 0.05, **p < 0.01. Unprocessed western blots, numerical data and exact p-values are available in the Source Data.

Article Snippet: Primary antibodies were: Lamin A/C (1:200, #10298-1-AP) from Proteintech or (1:200; #mab3538) from Millipore; Lamin B1 (1:200, #12987-1-AP), Lamin B2 (1:200, #10895-1-AP), LAP1 (1:200; #21459-1-AP) and Emerin (1:1,000, #10351-1-AP) from Proteintech; pSer19-MLC2 (1:200, #3671) from Cell Signaling); HA.11 (1:500, #901503) from BioLegend; Gamma-H2AX (1:600, #05-636) from Merck; 53BP1 (1:600, #NB100305) from Novus Biologicals; Mab414 (1:200, #ab24609) from Abcam.

Techniques: Migration, Expressing, Staining, Western Blot, Two Tailed Test